Meet The Professors Live 1

Select Publications

Albain K et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer (S8814,INT0100). San Antonio Breast Cancer Symposium 2007;Abstract 10.

Cameron D et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab:
Updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008;112(3):533-43. Abstract

Chia S et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women
with hormone receptor-positive, advanced breast cancer: Results from EFECT. J Clin Oncol 2008;26(10):1664-70. Abstract

Cuzick J et al; on behalf of the ATAC Trialists’ Group. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: A retrospective analysis of the ATAC trial. Lancet
Oncol 2008;9(12):1143-8. Abstract

Dang C et al. The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. J Clin Oncol
2008;26(8):1216-22. Abstract

Geyer CE et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355(26):2733-43. Abstract

Gnant M et al. Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12. Proc ASCO 2008;Abstract LBA4.

Goldstein LJ et al. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 2008;26(25):4063-71. Abstract

Hahn KM et al. Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer 2006;107(6):1219-26. Abstract

Johnson PH et al. The treatment of pregnant women with breast cancer and the outcomes of the children exposed to chemotherapy in utero. Proc ASCO 2005;Abstract 540.

Jones SE et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol
2006;24(34):5381-7. Abstract

Miles D et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. Proc ASCO 2008;Abstract LBA1011.

Miller K et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357(26):2666-76. Abstract

O’Shaughnessy J et al. A randomized study of lapatinib in combination with trastuzumab versus lapatinib monotherapy in heavily pretreated HER2+ metastatic breast cancer patients
progressing on trastuzumab therapy. Proc ASCO 2008;Abstract 1015.

Paik S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24(23):3726-34. Abstract

Slamon D et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. San Antonio Breast Cancer Symposium 2006;Abstract 52.

Sparano JA et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008;358(16):1663-71. Abstract

Von Minckwitz G et al. Capecitabine vs capecitabine + trastuzumab in patients with HER2- positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3-05). Proc ASCO 2008;Abstract 1025.